# Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes

> **NCT05105919** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Montreal Heart Institute** · enrollment: 50 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Aspirin 80 mg EC Tab

## Key facts

- **NCT ID:** NCT05105919
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-26
- **Primary completion:** 2024-04-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105919, "Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05105919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*